Beyond Acute Interstitial Nephritis: C3 Glomerulopathy as a Rare and Underrecognized Face of Immunotherapy Nephrotoxicity (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0701; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description A 73-year-old man with CKD stage 3b/4, baseline creatinine 2.9–3.1 mg/dL, metastatic NSCLC adenocarcinoma treated with carboplatin, pemetrexed, pembrolizumab, and radiation, prostate cancer, and Takotsubo cardiomyopathy presented with severe AKI on CKD several weeks after ICI exposure. Unlike primary C3GN, which is commonly treated with steroids and mycophenolate due to persistent complement dysregulation, ICI-induced C3GN may differ mechanistically. Complement blockade may warrant further study in steroid or rituximab-refractory cases, where ongoing complement activation may contribute to persistent inflammation"
Antibody-mediated Rejection • Cardiomyopathy • Chronic Kidney Disease • Complement-mediated Rare Disorders • Fibrosis • Genito-urinary Cancer • Glomerulonephritis • Immunology • Lung Adenocarcinoma • Lung Cancer • Lupus Nephritis • Nephrology • Non Small Cell Lung Cancer • Prostate Cancer • Renal Disease • Solid Tumor
|
|
Mahwash Siddiqi; Muhammad Raza; Maria Tahir; Naman Trivedi; Catherine Abendroth; Umar Farooq; Ronald P. Miller; Navin Verma; Nasrollah Ghahramani; Rafael Portela-Colon
|